The past decade has seen tremendous advances in our understanding of the genetic factors influencing response to a variety of drugs, including those targeted at treatment of cardiovascular diseases. In the case of clopidogrel, warfarin, and statins, the literature has become sufficiently strong that guidelines are now available describing the use of genetic information to guide treatment with these therapies

Angiotensin II Receptor Antagonists

  • Azilsartan (Edarbi®)
  • Candesartan (Atacand®)
  • Eprosartan (Teveten®)
  • Irbesartan (Avapro®)
  • Lorsartan (Cozaar®)
  • Olmesartan (Benicar®)
  • Telmisartan (Micardis®)
  • Valsartan (Diovan®)

Antianginal Agents

  • Ranolazine (Ranexa®)


  • Flecainide (Tambocor®)
  • Mexiletine (Mexitil®)
  • Propafenone (Rythmol®)


  • Clopidogrel (Plavix®)
  • Prasugrel (Effient®)
  • Ticagrelor (Brilinta®)
  • Vorapaxar (Zontivity®)


  • Torsemide (Demadex®)


  • Atorvastatin (Lipitor®)
  • Fluvastatin (Lescol®)
  • Lovastatin (Mevacor®)
  • Pitavastatin (Livalo®)
  • Pravastatin (Pravachol®)
  • Rosuvastatin (Crestor®)
  • Simvastatin (Zocor®)
Add test to cart Learn more